Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation

Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e579-e582. doi: 10.1016/j.clml.2021.02.008. Epub 2021 Mar 2.
No abstract available

Keywords: Allogeneic hematopoietic stem cell transplantation; Azacitidine; Blastic plasmacytoid dendritic cell neoplasm; Tagraxofusp; Treatment.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Azacitidine / administration & dosage*
  • Chemotherapy, Adjuvant / methods
  • Dendritic Cells / pathology
  • Hematologic Neoplasms / diagnosis
  • Hematologic Neoplasms / pathology
  • Hematologic Neoplasms / therapy*
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy*
  • Recombinant Fusion Proteins / administration & dosage*
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy*
  • Treatment Outcome

Substances

  • Recombinant Fusion Proteins
  • tagraxofusp
  • Azacitidine

Associated data

  • ClinicalTrials.gov/NCT03113643
  • ClinicalTrials.gov/NCT03485547
  • ClinicalTrials.gov/NCT04317781